Methoctramine tetrahydrochloride is a potent and cardioselectivity antagonist of M2 muscarinic receptor . Methoctramine tetrahydrochloride can inhibit Muscarine-induced bradycardia in vivo In Vitro Methoctramine tetrahydrochloride attenuates Acetylcholine (ACh)- and Arecaidine propargyl ester (APE)-induced increases in PG synthesis in a concentration-dependent manner. Methoctramine (0.01-1 μM) tetrahydrochloride causes facilitation of contractions induced by both pre- and postganglionic nerve stimulation in the guinea-pig isolated, innervated tracheal tube preparation. Methoctramine (≥10 μM) tetrahydrochloride reduces responses to both nerve stimulation and exogenous ACh. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Methoctramine (300 µg/kg; i.v.) tetrahydrochloride strongly inhibits the Methacholine- and Muscarine-induced bradycardia in the anaesthetized rat, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:M2 muscarinic receptor